Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank, announces that the Group granted options to subscribe for ordinary shares in the Group under the Cryo-Save Group 2009 Share Option Scheme on 4 April 2011.
The Group granted 20,000 options to Arnoud van Tulder, Chief Executive Officer, and 60,000 options to certain other employees of the Group all at an exercise price of €5.47 per share, being the price equal to the arithmetic average of the closing mid-market price over the five dealing days prior to the date of the grant. All of these options are exercisable at any time from 5 April 2014 until 5 April 2021.
The Group now has a total of 250,000 options over ordinary shares outstanding.
Enquiries:
| Cryo-Save Group | + 31 (0) 575 548 998 |
| Arnoud van Tulder, Chief Executive Officer | |
| SPJ Financiele Communicatie (The Netherlands) | +31 (0)20 647 8181 |
| Kees Jongsma/Leon Melens |
| Daniel Stewart & Company plc (UK) | + 44 (0) 20 7776 6550 |
| Christopher Theis | |
| College Hill (UK) | + 44 (0) 20 7457 2020 |
| Rozi Morris/ Adrian Duffield |
Free footage is available on www.videobankonline.com (http://www.videobankonline.com/).
About Cryo-Save (www.cryo-save.com)
Cryo-Save, the leading international family stem cell bank, already stores 170,000 samples from cord blood and umbilical cord tissue for newborns and adipose tissue for adults. These stem cells can mean the difference between life and death in the case of future threats to the health of the donors. There are already several diseases that can be cured by the use of stem cells, and the number of treatments will only increase. Driven by an international business strategy, Cryo-Save is now represented in 40 countries on three continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and France (validation in progress).
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Cryo-Save Group N.V. via Thomson Reuters ONE
